News

For the quarter ended March 2024, ProAssurance (PRA) reported revenue of $282 million, up 4.1% over the same period last year. EPS came in at $0.08, compared to -$0.15 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $269.24 million, representing a surprise of +4.74%. The company delivered an EPS surprise of +100.00%, with the consensus EPS estimate being $0.04.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how ProAssurance performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Combined Ratio: 111.6% versus 112.2% estimated by five analysts on average.
• Net Loss Ratio: 79.7% compared to the 81.8% average estimate based on five analysts.
• Underwriting Expense Ratio: 31.9% compared to the 30.4% average estimate based on five analysts.
• Underwriting Expense Ratio - Segregated Portfolio Cell Reinsurance: 33.3% versus the three-analyst average estimate of 31.4%.
• Net premiums earned: $244.15 million versus the five-analyst average estimate of $232.08 million. The reported number represents a year-over-year change of +1.8%.
• Net investment income: $33.90 million versus the five-analyst average estimate of $34.46 million. The reported number represents a year-over-year change of +11.8%.
• Equity in earnings (loss) of unconsolidated subsidiaries: $2.96 million versus $2 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a -364.3% change.
• Other income(loss): $3.96 million versus $2.70 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a +402.5% change.
• Net Premiums Earned- Specialty Property & Casualty: $188.89 million versus $182 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +5.3% change.
• Net Premiums Earned- Segregated Portfolio Cell Reinsurance: $14.17 million versus the three-analyst average estimate of $15.10 million. The reported number represents a year-over-year change of -7.4%.
• Net Premiums Earned- Workers Compensation: $41.09 million versus $40.48 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +0.7% change.
• Net investment income- Segregated Portfolio Cell Reinsurance: $0.69 million versus $0.67 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +65% change.

View all Key Company Metrics for ProAssurance here>>>

Shares of ProAssurance have returned +11.5% over the past month versus the Zacks S&P 500 composite's -1.6% change. The stock currently has a Zacks Rank #5 (Strong Sell), indicating that it could underperform the broader market in the near term.

Only $1 to See All Zacks' Buys and Sells

We're not kidding.

Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.

Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators,and more, that closed 228 positions with double- and triple-digit gains in 2023 alone.

See Stocks Now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

To read this article on Zacks.com click here.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.